drugset / Trial / NCT05882305
KSD-101 Therapy for EBV-associated Lymphomas: an Exploratory Clinical Trial
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to determine the tolerability and feasibility of KSD-101 in patients with EBV-associated haematologic neoplasms,to observe the characteristics of dose-limiting toxicity (DLT)and to explore the range of effective dose.
Timeline
- Start
- 2023-06-10
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
Outcome
Outcome not reported
Stopped (Enrollment): “No Participants Enrolled”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | KSD-101 | Cell therapy | 2.5e+06 cells | Subcutaneous |
| Subject | KSD-101 | Cell therapy | 1e+07 cells | Subcutaneous |